COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin

•COVID-19 infection may lead to Reversible Cerebral Vasoconstriction Syndrome (RCVS).•RCVS induced by COVID-19 infection is likely due to non-infectious process.•Mild COVID-19 infection can have cerebrovascular sequela despite rarity.•Brief course of nimodipine and aspirin may resolve COVID-19 induced RCVS.•Brief course of nimodipine and aspirin may be safe in COVID-19 induced RCVS. There have been limited cases linking SARS-CoV-2 infection with the development of reversible cerebral vasoconstriction syndrome (RCVS). We hereby report a rare case of RCVS in the setting of mild SARS-CoV-2 respiratory infection successfully treated with nimodipine and aspirin. SARS-CoV-2 attacks the ACE2-receptors, which are expressed in various body organs including the lungs, kidneys, and blood vessels. Vasoconstriction can result from down-regulation of the ACE2-receptors that can lead to sympathetic hypertonia of the cerebral blood vessel walls and/or over-activation of the renin-angiotensin axis.